Abstract
The SIGNIFY trial reported significantly more cases of atrial fibrillation with ivabradine treatment relative to placebo (508 vs. 362). It is quite clear that this arrhythmogenic effect warrants attention, given that it may prove to be the most serious adverse effect of ivabradine.
